InvestorsHub Logo
Followers 826
Posts 119567
Boards Moderated 15
Alias Born 09/05/2002

Re: willyw post# 2890

Saturday, 03/09/2024 2:16:45 PM

Saturday, March 09, 2024 2:16:45 PM

Post# of 2947

…I have almost stopped following the HBV space since the 514 asset seemed to have been shelved.

ENTA’s rationale for securing additional IP in HBV/HDV could be to seek royalties on GILD’s Hepludex rather than to support ENTA’s own HBV program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News